Menu

This site is intended for US
healthcare professionals only.

Important Safety Information Prescribing Information

EXPERT INSIGHTS

RESOURCES

See what the experts are saying about treatment with NINLARO® (ixazomib)

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

See new Thrombotic Microangiopathy Warning and Precaution in Important Safety Information at the bottom of this page.

NOW PLAYING
Play video of Dr Robert Vescio

The importance of long-term* proteasome inhibition in multiple myeloma

  • Dr. Vescio is a paid consultant of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
NOW PLAYING
Play video of Dr Stephen Noga and Dr Antonio Palumbo

The role of combination therapy in the long-term* treatment of multiple myeloma

  • Dr. Noga is an employee of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Dr. Palumbo, at the time of filming, was an employee of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Limited.
NOW PLAYING
Play video of Dr Ruben Niesvizky

Oral proteasome inhibition in the evolving multiple myeloma treatment landscape

  • Dr. Niesvizky is a paid consultant of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • *Defined as treatment to disease progression or unacceptable toxicity.
  • This content is intended for informational purposes only and is not a substitute for your clinical knowledge or professional judgment.